AnaptysBio

generalized pustular psoriasis

Chasing Boehringer, Anaptys hits goal in pivotal rare skin disease trial, plans out-licensing deal

Fierce Biotech

Mon, 10/9/23 - 10:11 am

generalized pustular psoriasis

Boehringer Ingelheim

Catalysts ahead for the smaller players

EP Vantage

Wed, 12/21/22 - 11:19 am

Calliditas Therapeutics

Eli Lilly

Esperion Therapeutics

Geron

Nektar Therapeutics

Oramed Pharmaceuticals

Pliant Therapeutics

Replimune

Selecta Biosciences

Swedish Orphan Biovitrum

Vera Therapeutics

Viking Therapeutics

AnaptysBio's HARP plays dud note, prompting rethink of imsidolimab strategy

Fierce Biotech

Thu, 09/1/22 - 10:46 am

Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials

hidradenitis suppurativa

Fierce Biotech

Wed, 06/29/22 - 10:51 am

AnaptysBio CEO Exits After Decade in the Role

BioSpace

Tue, 03/22/22 - 11:23 pm

Hamza Suria

Pharma CEOs

The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties

Endpoints

Tue, 10/26/21 - 10:46 am

Jemperli

GSK

AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure

Seeking Alpha

Tue, 03/9/21 - 10:55 am

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

palmoplantar pustulosis

Endpoints

Mon, 10/26/20 - 11:15 am

AnaptysBio's etokimab provides more disappointing results, raising questions about compound's future

Endpoints

Mon, 08/10/20 - 11:01 am

Here's Why AnaptysBio Rose 22.1% in May

Motley Fool

Tue, 06/9/20 - 11:26 pm

Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday

Motley Fool

Mon, 03/16/20 - 10:31 am

Top 7 Companies in Biotech Beach by Revenue

BioSpace

Thu, 12/5/19 - 10:15 am

Acadia Pharmaceuticals

Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Fierce Biotech

Thu, 11/14/19 - 10:23 am

AnaptysBio shares collapse after 'worst case scenario' for key drug

Biopharma Dive

Sun, 11/10/19 - 07:52 pm

etokimab

AnaptysBio Prepares for a Potential Gear Shift

Yahoo/Motley Fool

Sun, 08/11/19 - 01:25 pm

earnings

etokimab

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Yahoo/Benzinga

Sun, 07/28/19 - 11:48 pm

Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio

Stat

Fri, 06/21/19 - 10:00 am

monoclonal antibodies

REGN3500

Dupixent

AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool

Motley Fool

Tue, 08/7/18 - 08:43 pm